Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data

Basit Öğe Kaydı
dc.authorid0000-0003-1185-5816
dc.authorid0000-0002-2260-4660
dc.authorid0000-0001-6443-6426
dc.authorwosidGonullu, Emel/AAK-7851-2021
dc.authorwosidKanıtez, Nilüfer Alpay/W-7332-2019
dc.authorwosidBilgin, Emre/C-8092-2015
dc.contributor.authorKimyon, G.
dc.contributor.authorKalyoncu, U.
dc.contributor.authorKiraz, S.
dc.contributor.authorBeş, C.
dc.contributor.authorCoşkun, N.
dc.contributor.authorYağız, B.
dc.contributor.authorErtenli, I
dc.contributor.authorMercan, Rıdvan
dc.date.accessioned2022-05-11T14:05:02Z
dc.date.available2022-05-11T14:05:02Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.
dc.description.sponsorshipHacettepe Rheumatology Society
dc.description.sponsorshipthis study was funding by Hacettepe Rheumatology Society. Competing interests: see page 858.
dc.identifier.endpage858
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue4en_US
dc.identifier.pmid32896266
dc.identifier.startpage852
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4876
dc.identifier.volume39
dc.identifier.wosWOS:000691869100019
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorMercan, Rıdvan
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical And Experimental Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectleflunomide
dc.subjectmethotrexate
dc.subjectrheumatoid arthritis
dc.subjectbiologic or targeted-synthetic DMARDs
dc.subjectCombination
dc.subjectTherapy
dc.subjectManagement
dc.subjectMonotherapy
dc.titleBiological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu